Boston Scientific (BSX) is back in focus after a cyberattack disrupted third quarter 2026 operations, contributing to softer sales trends in electrophysiology and WATCHMAN devices and prompting lower guidance along with a restructuring plan.
At a share price of US$41.98, Boston Scientific has seen momentum fade, with the stock down 8.12% on a 7 day share price return and the 1 year total shareholder return declining 58.32% as cyberattack disruption, product recall headlines and softer guidance reset expectations.
Scan how other healthcare device players are responding to similar shocks by reviewing the handpicked 34 healthcare AI stocks that could benefit as algorithms and data security move further up the priority list.
Boston Scientific now trades about 18% below the average analyst target and roughly 40% below some intrinsic value estimates after the selloff. Is that discount compensation for cyber and growth risk, or is it a clear overreaction?
Most Popular Narrative: 27% Undervalued
Against a narrative fair value of $57.82 and a last close of $41.98, Boston Scientific screens as materially discounted, with the cyberattack and product specific pressure set against a longer multi year recovery story built around interventional cardiology and restructuring.
The main factor that has to go right is that interventional cardiology and vascular therapies continue to grow solidly and that acquisitions like Penumbra and the MiRus TAVR option integrate effectively enough to offset weaker EP and LAAC demand and the impact of the cyberattack.
The current valuation implies the market is discounting the shares for near term growth and margin pressure more than this narrative judges warranted, given the planned restructuring savings, capital returns, and expansion into large adjacencies.
See why 88 investors see Boston Scientific as 27% undervalued.
Result: Fair Value of $57.82 (UNDERVALUED)
Still, if electrophysiology softness persists and the eight day cyberattack leaves a longer shadow on execution, the Boston Scientific recovery narrative could prove to be too optimistic.
Find out about the key risks to this Boston Scientific narrative.
Next Steps
With sentiment split between cyber risks and recovery potential, act while the debate is fresh and weigh both sides by reviewing the 3 key rewards and 1 important warning sign.
Looking for more Boston Scientific style investment ideas?
If Boston Scientific has sharpened your focus on risk and reward, do not stop here. Broaden your watchlist using targeted screeners built from hard numbers.
- Target potential mispriced opportunities by scanning the 29 high quality undervalued stocks that combine quality fundamentals with discounted valuations.
- Strengthen the defensive side of your portfolio through a list of solid balance sheet and fundamentals (25 results) that can help you focus on financial resilience.
- Hunt for fresh potential by reviewing a 18 high quality undiscovered gems list that highlights quality businesses flying under most investors' radar.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com